Dr Angela Lamarca discusses approaches to first- and second-line therapy for patients with advanced CCA. She touches on current standards of care with combination chemotherapy, and the fact that a change from first-line to second-line therapy is usually done when there is evidence of radiographic progression of disease on first-line therapy. Dr Lamarca looks to the future when the use of molecular profiling may open the door to targeted therapies.